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Optimizing Platelet Inhibition in
Clopidogrel Poor Metabolizers
Therapeutic Options and Practical Considerations*
Dominick J. Angiolillo, MD, PHD, Masafumi Ueno, MD
Jacksonville, Florida
Dual antiplatelet therapy with aspirin and clopidogrel rep-
resents the standard of care for the prevention of recurrent
ischemic events in patients undergoing percutaneous coro-
nary intervention with stent placement. However, some
patients have impaired clopidogrel response and thus persist
with high on-treatment platelet reactivity (HOPR), result-
ing in an increased risk of atherothrombotic events (1). This
an be attributed to several factors, such as genetic poly-
orphisms regulating the activity of the cytochrome P450
CYP) 2C19 enzyme, which is key in metabolizing clopi-
ogrel into its active metabolite (2,3).
See pages 381, 392, and 403
The boxed warning recently added to the clopidogrel label
underscoring the potential risk of adverse cardiovascular
outcomes among patients with a “poor metabolizer” geno-
type (defined as subjects with 2 loss-of-function [LOF]
alleles) and advocating the use of other antiplatelet medi-
cations or alternative dosing strategies for these subjects (4),
has led to investigations of treatment options associated
with more optimal platelet inhibition. These include
increasing clopidogrel dosing, adding a third antiplatelet
agent (e.g., cilostazol), and switching to a novel genera-
tion P2Y12 inhibitor (e.g., prasugrel, ticagrelor, cangre-
or) (Fig. 1). In this issue of JACC: Cardiovascular
nterventions, the results of 3 independent investigations
ssessing these strategies among patients more prone to
*Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the Department of Medicine-Division of Cardiology, University of Florida
ollege of Medicine–Jacksonville, Jacksonville, Florida. Dr. Angiolillo reports receiv-
ng honoraria for lectures from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly Co.,
nd Daiichi Sankyo, Inc; consulting fees from Bristol-Myers Squibb, Sanofi-Aventis,
LI Lilly Co., Daiichi Sankyo, Inc., AstraZeneca, The Medicines Company, Portola,
ovartis, Medicure, Accumetrics, Arena Pharmaceuticals, Merck, and Evolva; and
esearch grants from Bristol-Myers Squibb, Sanofi-Aventis, GlaxoSmithKline, Ot-
uka, Boston Scientific, Eli Lilly Co., Daiichi Sankyo, Inc., The Medicines Company,b
ortola, Accumetrics, Schering-Plough, AstraZeneca, Eisai, and Johnson & Johnson.
r. Ueno has reported that he has no relationships to disclose.oorly metabolize clopidogrel based on the presence of
YP2C19 LOF alleles are reported and provide important
nsights on this ever-rising clinical quandary (5–7).
The ability of clopidogrel loading-dose (LD) regimens to
vercome “genetic resistance” was investigated by Collet et
l. (5), who assessed in a prospective, crossover, randomized
ashion, pharmacokinetic and pharmacodynamic (PD) re-
ponses to a standard (300-mg) versus a high (900-mg) LD
f clopidogrel according to the carrier status of the
YP2C19*2 LOF allele. The results of this study corrobo-
ate that carriers of CYP2C19*2 have a reduced response to
standard LD with a gene-dose effect (wild-type [wt]
omozygous  wt/*2 heterozygous  *2/*2 homozygous) and
emonstrate that the use of a high LD regimen can
vercome genetic resistance among heterozygous but not
omozygous carriers of LOF alleles. The comprehensive
harmacokinetic assessments in this study correlate well
ith the PD findings and provide confirmatory data to support
he inability of “poor metabolizers” to efficiently generate active
etabolite despite high dosing of clopidogrel. Although these
esults provide insights into a treatment alternative to opti-
ize platelet inhibition among heterozygous subjects, and
learly argue against a high LD strategy for homozygous
OF allele carriers, perplexity remains on the use of this
reatment option. In fact, in addition to the lack of efficacy
ata, concerns emerge over the safety (liver toxicity) and
racticality (long-term high LD regimens) of this strategy
o overcome a fixed trait represented by our genetic patri-
ony for the treatment of a chronic illness process such as
oronary artery disease. This emphasizes the need to define
he ideal “maintenance” treatment regimen to optimize
latelet inhibition among poor metabolizers.
Studies using a high (150-mg) maintenance dose (MD)
f clopidogrel have been disappointing. In fact, investiga-
ions have shown that rates of HOPR remain elevated
mong CYP2C19 LOF allele carriers, particularly homozy-
ous patients, even with a high MD regimen (8,9). These
ndings have also been corroborated by the investigations
rom Kim et al. (6) and Alexopoulos et al. (7) reported in
his issue of JACC: Cardiovascular Interventions. Further,
hese pharmacogenetic studies are in line with prior PD
tudies showing that high MD is associated with only
odest antiplatelet effects (10,11). This may have also
ontributed to why high MD failed to improve outcomes in
he GRAVITAS (Gauging Responsiveness With A Veri-
yNow Assay–Impact On Thrombosis And Safety) trial
11). Overall, the aforementioned findings from PD, phar-
acogenetic, and clinical outcome studies argue against
ncreasing clopidogrel dosing among poor metabolizers or
atients with HOPR as a strategy to optimize platelet
nhibition, and further emphasizes the need for alternative
pproaches.
Cilostazol is a phosphodiesterase-III inhibitor approved
y the U.S. Food and Drug Administration for relief of
orylat
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412peripheral vascular disease symptoms. Cilostazol has pleio-
tropic effects; it exerts its mechanism of action, not only on
platelets, but also on smooth muscle and endothelial cells
(12). Numerous studies have shown that adjunctive cilosta-
zol therapy, referred to as “triple antiplatelet therapy,”
enhances platelet inhibition and reduces rates of HOPR
Figure 1. Therapeutic Options for Optimizing Platelet Inhibition in Clopidog
Clopidogrel is a prodrug, which, after intestinal absorption, undergoes 2-step h
CYP1A2 are involved in 1 step; CYP2B6, CYP2C19 are involved in both steps) t
processes through irreversible blockade of the P2Y12 receptor. Approximately
pound, thus, only 15% is available for hepatic metabolism. Genetic polymorph
metabolism can affect platelet inhibitory effects, intestinal absorption, P-glycop
CYP2C19 loss-of function alleles), and platelet membrane receptors (e.g., P2 re
enhanced platelet inhibition in poor metabolizers, which may be achieved by
intestinal absorption process. However, in contrast to clopidogrel, esterases ar
to its active metabolite via a single CYP-dependent step. Direct-acting antiplat
require hepatic metabolism for pharmacodynamic activity. Ticagrelor and cilos
tion by direct blockade of the P2Y12 receptor and PDE-III, respectively. Cangre
ing intestinal absorption. Genetic polymorphisms of target proteins/enzymes (
inhibition do not affect the pharmacodynamic activity of prasugrel, cilostazol,
tion processes by modulating intraplatelet levels of cAMP and VASP-P. Solid b
AC  adenylyl cyclase; ADP  adenosine diphosphate; ATP  adenosine triph
III (PDEIII); PGE1  prostaglandin E1; PKA  protein kinases; VASP-P  phosphcompared with dual antiplatelet therapy, even when high uclopidogrel MD is used (13–15). Overall, these findings
may explain why triple antiplatelet therapy has been
associated with better clinical outcomes compared with
dual antiplatelet therapy, particularly in high-risk set-
tings, although this has not been confirmed in more
recent investigations (16). Kim et al. (6) expand our
or Metabolizers
c oxidation by cytochrome P450 (CYP) 2C19 enzymes (CYP3A, CYP2C9,
erate an active metabolite that inhibits platelet activation and aggregation
f clopidogrel is hydrolyzed pre-hepatically by esterases into an inactive com-
ncoding for proteins/enzymes at various levels modulating clopidogrel
(encoded by ABCB1 gene), hepatic metabolism, CYP enzymes (particularly
s). Increasing the clopidogrel dose is not consistently associated with
strategies. Prasugrel, like clopidogrel, is also an oral prodrug with a similar
of prasugrel’s activation pathway, and prasugrel is oxidized more efﬁciently
gents (cangrelor, ticagrelor, and cilostazol) have reversible effects and do not
re administered orally and, after intestinal absorption, inhibit platelet activa-
dministered intravenously, and directly inhibits the P2Y12 receptor, bypass-
ne, liver, and platelet membrane) modulating clopidogrel-mediated platelet
lor, and cangrelor, which ultimately inhibit platelet activation and aggrega-
rrows indicate activation. Dotted black arrows indicate inhibition.
te; cAMP  cyclic adenosine monophosphate; PDE-III  phosphodiesterase
ion of vasodilator-stimulated phosphoprotein.rel Po
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413therapy according to the carrier status of LOF alleles of
CYP2C19 in patients undergoing primary percutaneous
coronary intervention. In particular, triple antiplatelet ther-
apy was associated with significant changes in PD measures
as well as rates of HOPR compared with high clopidogrel
MD among LOF allele carriers. However, changes in PD
measures as well as rates of HOPR were not statistically
different among noncarriers of LOF alleles. Overall, these
findings are in line with recently reported results (17) and
suggest that triple antiplatelet therapy may be a better
option compared with high MD clopidogrel to achieve
greater platelet inhibitory effects and reduce rates of HOPR
only among carriers of LOF alleles of the CYP2C19 gene.
Unlike other investigations in this study, pre-discharge values
of platelet reactivity were similar between noncarriers and
carriers of LOF alleles, which might be explained by the
small sample size or variability in PD measures associated
with genetic testing. Although no patient discontinued
cilostazol therapy in the present study, cilostazol is associ-
ated with a high rate of nonbleeding side effects (e.g.,
headache, tachycardia, palpitations, gastrointestinal distur-
bances), which is known to be associated with elevated (15%
to 20%) rates of treatment discontinuation (13). Further, it
should be kept in mind that the increase in heart rate
associated with cilostazol therapy, and its contraindications
in the presence of a low ejection fraction, limit the use of
this drug among patients with an acute coronary syndrome
or congestive heart failure.
Novel P2Y12 inhibitors, such as prasugrel and ticagrelor,
are characterized by more potent antiplatelet effects and
reduce recurrent ischemic event rates compared with clopi-
dogrel among acute coronary syndrome patients (18). No-
tably, the effects of these agents are not attenuated by factors
interfering with CYP2C19 activity such as genetic polymor-
hisms or other drugs (e.g., omeprazole) (19). Therefore,
hese may be attractive alternatives for patients with “resis-
ance” defined by genetic or platelet function testing. In
heir prospective, randomized, crossover investigation,
lexopoulos et al. (7) assessed the PD effects of prasugrel
10 mg/day) versus high-MD clopidogrel (150 mg/day) in
atients with HOPR. These patients were also stratified
ccording to CYP2C19*2 carrier status. The study showed
rasugrel to be more effective compared with high clopi-
ogrel MD in reducing platelet reactivity and rates of
OPR, irrespective of genetic background, although this
as more pronounced among LOF allele carriers. These
ata are consistent with that reported in a case series
howing that only prasugrel, and not escalating doses of
lopidogrel, was able to enhance platelet inhibition in
atients with “clinical resistance” to clopidogrel presenting
s stent thrombosis (20). Although switching to prasugrel
herapy does not raise any concerns on PD interactions (21),
nd thus remains an attractive solution to treat patients with
OPR or poor clopidogrel metabolizers, it should be aointed out that novel P2Y12 receptor antagonists are
ssociated with an increased risk of spontaneous bleeding
18). Importantly, bleeding has emerged as an important
redictor of poor long-term outcomes, including in-
reased mortality, and therefore the potential benefits
ssociated in terms of reduction of ischemic events need
o be kept in perspective with known bleeding complica-
ions (22). In contrast to the novel P2Y12 receptor antagonists,
studies with cilostazol have not shown an increase in
bleeding. This is likely attributable to the specific pharma-
cological properties of cilostazol (12), and making it an
option for patients in whom greater platelet inhibition is
required, particularly if bleeding is a concern or if novel
P2Y12 inhibitors are contraindicated.
Ultimately, it is important to highlight that the boxed
warning on CYP2C19 genotypes allude to subjects who have
2 LOF alleles (“poor metabolizers”), which occurs in 2% to
14% of the population, depending on racial background (4).
The prevalence of LOF alleles is higher in Asian popula-
tions. Accordingly, 61% of patients in the study from Kim
et al. (6) were carriers of LOF alleles, and 15% were poor
clopidogrel metabolizers. However, analyses were only per-
formed according to carrier status of LOF alleles, mostly
represented by heterozygous or “intermediate metabolizers,”
and therefore, the impact of cilostazol on poor metabolizers
in this study population remains elusive. On the contrary,
Alexopoulos et al. (7) did not find any patient in their study
with a poor metabolizer genotype. Therefore, the impact of
prasugrel from this study cohort cannot be extrapolated,
although prior investigations have shown that prasugrel can
enhance platelet inhibition in these patients whereas high
LD clopidogrel cannot (5,20). It is important to appreciate
that although the prevalence of only 1 LOF allele (“inter-
mediate metabolizers”) is more common (30% to 60%,
depending on racial background) and has also been inde-
pendently associated with atherothrombotic events (23),
this genotype is associated with a broad spectrum of
response profiles to clopidogrel. As a result, PD measures
among intermediate metabolizers overlap considerably with
those of other genotypes (ultra, extensive, and poor metabo-
lizers) (24). This is in line with the fact that CYP2C19
enotypes contribute only in part to the PD effects of
lopidogrel, and numerous other genetic, clinical, and cel-
ular factors are determinants of platelet reactivity (Fig. 1)
2). Because of this, it is questionable whether individual-
zing antiplatelet therapy should be based on genetic testing,
latelet function testing, or both (25). Indeed, the seminal
nvestigations reported in this issue represent a step forward
n answering some important questions. However, the
esults of ongoing large-scale outcome studies, which are
valuating the safety and efficacy of individualizing anti-
latelet treatment strategies, are needed before its routine
pplication can make its way into clinical practice (1,4).
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